These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17706458)

  • 1. Structural requirements for uptake and recognition of CpG oligonucleotides.
    Heeg K; Dalpke A; Peter M; Zimmermann S
    Int J Med Microbiol; 2008 Jan; 298(1-2):33-8. PubMed ID: 17706458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopharmacology of CpG DNA.
    Dalpke A; Zimmermann S; Heeg K
    Biol Chem; 2002 Oct; 383(10):1491-500. PubMed ID: 12452427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
    Harandi AM; Holmgren J
    Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG-DNA as immune response modifier.
    Dalpke AH; Heeg K
    Int J Med Microbiol; 2004 Oct; 294(5):345-54. PubMed ID: 15532993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-stranded RNA- and CpG DNA-induced immune responses in Atlantic salmon: comparison and synergies.
    Strandskog G; Skjaeveland I; Ellingsen T; Jørgensen JB
    Vaccine; 2008 Aug; 26(36):4704-15. PubMed ID: 18602433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
    Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
    Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells.
    Devilder MC; Allain S; Dousset C; Bonneville M; Scotet E
    J Immunol; 2009 Sep; 183(6):3625-33. PubMed ID: 19710464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
    Wong KL; Tang LF; Lew FC; Wong HS; Chua YL; MacAry PA; Kemeny DM
    J Immunol; 2009 Jul; 183(1):41-50. PubMed ID: 19535645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E; Vollmer J
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing immunogenicity by CpG DNA.
    Jiang W; Pisetsky DS
    Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG DNA in the prevention and treatment of infections.
    Dalpke A; Zimmermann S; Heeg K
    BioDrugs; 2002; 16(6):419-31. PubMed ID: 12463765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
    Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
    J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.
    Kovacs-Nolan J; Mapletoft JW; Latimer L; Babiuk LA; Hurk Sv
    Vaccine; 2009 Mar; 27(14):2048-54. PubMed ID: 19428829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG motifs to modulate innate and adaptive immune responses.
    Vollmer J
    Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles.
    Malyala P; O'Hagan DT; Singh M
    Adv Drug Deliv Rev; 2009 Mar; 61(3):218-25. PubMed ID: 19168103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.